86 results on '"Mitlak, Bruce"'
Search Results
2. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe
3. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study
4. Pharmaceutical Treatments of Osteoporosis
5. List of Contributors
6. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend
7. Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
8. The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial
9. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project
10. Pharmaceutical Treatments of Osteoporosis
11. List of Contributors
12. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
13. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
14. Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice
15. Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
16. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis
17. Regulatory Considerations for the Design and Conduct of Osteoporosis Registration Trials
18. Contributors
19. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
20. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
21. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
22. Abstract #796012: Phase 1B Evaluation of the Pharmacokinetics and Pharmacodynamics of Abaloparatide Solid Microstructured Transdermal System in Postmenopausal Women with Low Bone Mineral Density
23. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
24. Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
25. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
26. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial
27. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis
28. OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
29. Abstract #184 Effect of Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Type 2 Diabetes Mellitus
30. OR03-2 Different Effects of Abaloparatide and h-PTH(1-34) on Osteoclastogenesis and Bone Resorption
31. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption
32. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
33. Abstract #531 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Type 2 Diabetes Mellitus
34. Abstract #530 Effect of Abaloparatide Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women with Osteoporosis
35. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial
36. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
37. The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density
38. A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
39. REGIONAL MYOCARDIAL PERFUSION MEASURED BY HYDROGEN WASHOUT
40. Bone mineral measurements by DXA in animals
41. Quality of Life in Sarcopenia and Frailty
42. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
43. Effect of blosozumab on bone mineral density: results of a phase 2 study of postmenopausal women with low bone mineral density
44. Femoral strength in osteoporotic women treated with teriparatide or alendronate
45. Long-term raloxifene for postmenopausal osteoporosis
46. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA
47. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
48. Effect of Raloxifene on All-cause Mortality
49. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
50. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.